SCHEMBL4151869

SCHEMBL4151869

CCCC(=O)Oc1ccc(-c2ccc3c(c2COc2cc(F)ccc2C)N(C)C(=O)C(C)(C)N3)c(OC)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IL6 P05231 8/20 0.75
ALDH1A1 P00352 4/20 0.34
MAPT P10636 4/20 0.34
LMNA P02545 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
RET P07949 1/20 0.32
ADORA2B P29275 1/20 0.32
HTR2C P28335 1/20 0.32
KDM4E B2RXH2 2/20 0.31
GAA P10253 2/20 0.31
KMT2A Q03164 2/20 0.31
GLA P06280 1/20 0.31
HTT P42858 2/20 0.31
TP53 P04637 1/20 0.31
G6PD P11413 1/20 0.31
GFER P55789 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580655 0.94 IL6 (0.77) IL6ALDH1A1MAPTLMNANPSR1
SCHEMBL4141576 0.91 IL6 (0.81) IL6FFAR1FFAR4ADORA2BHTR2C
SCHEMBL4581073 0.91 IL6 (0.78) IL6ALDH1A1FFAR1FFAR4ADORA2B
SCHEMBL4581010 0.91 IL6 (0.69) IL6ALDH1A1MAPTLMNANPSR1
SCHEMBL4581521 0.89 IL6 (0.71) IL6ALDH1A1MAPTADORA2BKDM4E
SCHEMBL4581524 0.89 IL6 (0.73) IL6ALDH1A1MAPTLMNANPSR1
SCHEMBL4582397 0.89 IL6 (0.72) IL6
SCHEMBL4581163 0.89 IL6 (0.82) IL6ALDH1A1FFAR1FFAR4HTR2C
SCHEMBL4579570 0.89 IL6 (0.75) IL6FFAR1FFAR4HTR2C
SCHEMBL4144984 0.89 IL6 (0.75) IL6FFAR1FFAR4HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10435379-B2 [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2019-10-08 US disclosed
US-10435379-B2 [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2019-10-08 US disclosed
US-20190106393-A1 [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF SANTEN PHARMACEUTICAL CO., LTD. (JP) 2019-04-11 US disclosed
US-20190106393-A1 [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF SANTEN PHARMACEUTICAL CO., LTD. (JP) 2019-04-11 US disclosed
US-10189796-B2 [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2019-01-29 US disclosed
US-10189796-B2 [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2019-01-29 US disclosed
US-20180244633-A1 [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF SANTEN PHARMACEUTICAL CO., LTD. (JP) 2018-08-30 US disclosed
EP-3342768-A1 [4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF Santen Pharmaceutical Co., Ltd. (JP) 2018-07-04 EP disclosed
EP-3342768-A1 [4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF Santen Pharmaceutical Co., Ltd. (JP) 2018-07-04 EP disclosed
WO-2017034006-A1 [4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF 参天製薬株式会社 2017-03-02 WO disclosed
US-8551991-B2 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
US-8551991-B2 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
US-8551991-B2 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-1995242-B1 NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY SANTEN PHARMACEUTICAL CO LTD (JP) 2012-11-07 EP disclosed
EP-1995242-B1 NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY SANTEN PHARMACEUTICAL CO LTD (JP) 2012-11-07 EP disclosed
US-20090111807-A1 Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-04-30 US disclosed
US-20090111807-A1 Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-04-30 US disclosed
US-20090111807-A1 Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-04-30 US disclosed
EP-1995242-A1 NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2008-11-26 EP disclosed
EP-1995242-A1 NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189796-B2 [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof NR3C2, NR3C1, GRK4 IL6 1589/4885ALDH1A1 3096/4885MAPT 3875/4885
US-10435379-B2 [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof NR3C2, NR3C1, MC2R IL6 1316/4885ALDH1A1 3034/4885MAPT 2394/4885
US-20190106393-A1 [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF NR3C2, NR3C1, MC2R IL6 1316/4885ALDH1A1 3034/4885MAPT 2394/4885
US-20180244633-A1 [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF NR3C2, NR3C1, GRK4 IL6 1589/4885ALDH1A1 3096/4885MAPT 3875/4885
US-20090111807-A1 Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity NR3C1, NR3C2, MC2R IL6 3728/4885ALDH1A1 3680/4885MAPT 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.